TABLE 2.
Frequencies of HTT IAs in the different cohorts.
| Neuropathology | N genotyped | HTT IAs N (%) | p‐value (corrected)* | OR [CI 95%] | HTT pathological expansions N (%) | p‐value (corrected)* | OR [CI 95%] |
|---|---|---|---|---|---|---|---|
|
CBD n=34 |
34 | 0 (0) | 1.000 | 0.00 [0.00–3.16] | 2 (5.9) | 0.0353** | 31.20 [2.20–438.26] |
|
PSP n = 98 |
96 | 4 (4.2) | 1.000 | 1.10 [0.28–3.13] | 2 (2.1) | 0.037*** | 11.20 [0.80–153.12] |
|
AD n = 456 |
455 | 28 (6.2) | 0.359 | 1.62 [0.95–2.73] | 1 (0.2) | 1.000 | 1.19 [0.02–22.90] |
|
LO‐AD n = 363 |
362 | 24 (6.6) | 0.404 | 1.76 [1.00–3.03] | 1 (0.3) | 1.000 | 1.50 [0.03–28.95] |
|
EO‐AD n = 93 |
93 | 4 (4.3) | 1.000 | 1.11 [0.28–3.17] | 0 (0.0) | 1.000 | 0.00 [0.00–60.95] |
|
Controls n = 1070 |
1056 | 41 (3.9) | 2 (0.2) |
Abbreviations: CI, confidence interval; OR, odds ratio.
*
The threshold of significant p‐value is set below 0.05.
**
HTT pathological expansions CBD, versus controls and AD.
***
HTT pathological expansions PSP versus controls. AD, Alzheimer's disease; CBD, corticobasal degeneration; EO‐AD, early onset AD; LO‐AD, late onset AD; PSP, progressive supranuclear palsy.